Scientists presented the complete results of a Phase I trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T cell therapy for the treatment of recurrent glioblastoma. [Nature Medicine] Abstract
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.